Prolongation of Survival of Dogs with Oral Malignant Melanoma Treated by En Bloc Surgical Resection and Adjuvant CSPG4-antigen Electrovaccination

Overview

Journal Vet Comp Oncol

Specialties Oncology
Veterinary Medicine

Date 2016 May 6

PMID 27146852

Citations 25

Authors

L A Piras

F Riccardo

S Iussich

L Maniscalco

F Gattino

M Martano

E Morello

S Lorda Mayayo

V Rolih

F Garavaglia

R De Maria

E Lardone

F Collivignarelli

D Mignacca

D Giacobino

S Ferrone

F Cavallo

P Buracco

Affiliations

Soon will be listed here.

Abstract

Reported post-surgery 1-year survival rate for oral canine malignant melanoma (cMM) is around 30%; novel treatments are needed as the role of adjuvant chemotherapy is unclear. This prospective study regards adjuvant electrovaccination with human chondroitin sulfate proteoglycan-4 (hCSPG4)-encoded plasmid in 23 dogs with resected II/III-staged CSPG4-positive oral cMM compared with 19 dogs with resected only II/III-staged CSPG4-positive oral cMM. Vaccination resulted in 6-, 12-, 18- and 24-month survival rate of 95.6, 73.9, 47.8 and 30.4%, respectively [median survival time (MST) 684 days, range 78-1694, 8 of 23 dogs alive] and 6-, 12-, 18- and 24-month disease-free interval (DFI) rate of 82.6, 47.8, 26.1 and 17.4%, respectively (DFI 477 days, range 50-1694). Non-vaccinated dogs showed 6-, 12-, 18- and 24-month survival rate of 63.2, 26.3, 15.8 and 5.3%, respectively (MST 200 days, range 75-1507, 1 of 19 dogs alive) and 6-, 12-, 18- and 24-month DFI rate of 52.6, 26.3, 10.5 and 5.3%, respectively (DFI 180 days, range 38-1250). Overall survival and DFI of vaccinated dogs was longer in those <20 kg. In vaccinated and non-vaccinated dogs local recurrence rate was 34.8 and 42%, respectively while lung metastatic rate was 39 and 79%, respectively.

Citing Articles

Clinical evaluation of HuDo-CSPG4 DNA electroporation as adjuvant treatment for canine oral malignant melanoma: comparison of two vaccination protocols.

Camerino M, Giacobino D, Tarone L, Dentini A, Martano M, Morello E Vet Q. 2025; 45(1):1-16.

PMID: 40059815 PMC: 11894750. DOI: 10.1080/01652176.2025.2473717.

APAVAC Immunotherapy for the Adjuvant Treatment of a Canine Mucosal Melanoma.

Rinaldi V, Bongiovanni L, Crisi P, Vignoli M, Peli R, Masci S Vet Sci. 2024; 11(12).

PMID: 39728968 PMC: 11680214. DOI: 10.3390/vetsci11120628.

Risk stratification scheme based on the TNM staging system for dogs with oral malignant melanoma centered on clinicopathologic presentation.

Song E, Lawrence J, Greene E, Christie A, Goldschmidt S Front Vet Sci. 2024; 11:1472748.

PMID: 39386252 PMC: 11463030. DOI: 10.3389/fvets.2024.1472748.

Establishment of Primary Cell Cultures from Canine Oral Melanomas via Fine-Needle Aspiration: A Novel Tool for Tumorigenesis and Cancer Progression Studies.

Lo Giudice A, Porcellato I, Pellegrini M, Rottenberg S, He C, Dentini A Animals (Basel). 2024; 14(13).

PMID: 38998060 PMC: 11240394. DOI: 10.3390/ani14131948.

The diagnostic yield of preoperative screening for oral cancer in dogs over 15 years, part 1: locoregional screening.

Goldschmidt S, Soltero-Rivera M, Quiroz A, Wong K, Rebhun R, Zwingenberger A J Am Vet Med Assoc. 2023; 261(S2):S14-S23.

PMID: 37863103 PMC: 10956222. DOI: 10.2460/javma.23.05.0299.

References

Kosovsky J, Matthiesen D, Marretta S, Patnaik A . Results of partial mandibulectomy for the treatment of oral tumors in 142 dogs. Vet Surg. 1991; 20(6):397-401. DOI: 10.1111/j.1532-950x.1991.tb00346.x. View

Rassnick K, Ruslander D, Cotter S, Al-Sarraf R, Bruyette D, Gamblin R . Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc. 2001; 218(9):1444-8. DOI: 10.2460/javma.2001.218.1444. View

Riccardo F, Iussich S, Maniscalco L, Lorda Mayayo S, La Rosa G, Arigoni M . CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clin Cancer Res. 2014; 20(14):3753-62. PMC: 8656093. DOI: 10.1158/1078-0432.CCR-13-3042. View

Finocchiaro L, Fondello C, Gil-Cardeza M, Rossi U, Villaverde M, Riveros M . Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma. Hum Gene Ther. 2015; 26(6):367-76. PMC: 4492668. DOI: 10.1089/hum.2014.130. View

Cancedda S, Rohrer Bley C, Aresu L, Dacasto M, Leone V, Pizzoni S . Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma. Vet Comp Oncol. 2014; 14(4):e146-e157. DOI: 10.1111/vco.12122. View

Boston S, Lu X, Culp W, Montinaro V, Romanelli G, Dudley R . Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001-2012). J Am Vet Med Assoc. 2014; 245(4):401-7. DOI: 10.2460/javma.245.4.401. View

Dow S, Elmslie R, Willson A, Roche L, Gorman C, POTTER T . In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest. 1998; 101(11):2406-14. PMC: 508830. DOI: 10.1172/JCI510. View

Culp W, Ehrhart N, Withrow S, Rebhun R, Boston S, Buracco P . Results of surgical excision and evaluation of factors associated with survival time in dogs with lingual neoplasia: 97 cases (1995-2008). J Am Vet Med Assoc. 2013; 242(10):1392-7. DOI: 10.2460/javma.242.10.1392. View

Blackwood L, Dobson J . Radiotherapy of oral malignant melanomas in dogs. J Am Vet Med Assoc. 1996; 209(1):98-102. View

10.

Esplin D . Survival of dogs following surgical excision of histologically well-differentiated melanocytic neoplasms of the mucous membranes of the lips and oral cavity. Vet Pathol. 2008; 45(6):889-96. DOI: 10.1354/vp.45-6-889. View

11.

Treggiari E, Grant J, North S . A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma. J Vet Med Sci. 2016; 78(5):845-50. PMC: 4905841. DOI: 10.1292/jvms.15-0510. View

12.

Ramos-Vara J, Miller M . Immunohistochemical identification of canine melanocytic neoplasms with antibodies to melanocytic antigen PNL2 and tyrosinase: comparison with Melan A. Vet Pathol. 2010; 48(2):443-50. DOI: 10.1177/0300985810382095. View

13.

Cavallo F, Aurisicchio L, Mancini R, Ciliberto G . Xenogene vaccination in the therapy of cancer. Expert Opin Biol Ther. 2014; 14(10):1427-42. DOI: 10.1517/14712598.2014.927433. View

14.

Dewhirst M, Sim D, Forsyth K, Grochowski K, Wilson S, BICKNELL E . Local control and distant metastases in primary canine malignant melanomas treated with hyperthermia and/or radiotherapy. Int J Hyperthermia. 1985; 1(3):219-34. DOI: 10.3109/02656738509029287. View

15.

Sardesai N, Weiner D . Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. 2011; 23(3):421-9. PMC: 3109217. DOI: 10.1016/j.coi.2011.03.008. View

16.

Seo K, Coh Y, Rebhun R, Ahn J, Han S, Lee H . Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines. Res Vet Sci. 2014; 96(3):482-6. PMC: 5021445. DOI: 10.1016/j.rvsc.2014.03.003. View

17.

Grosenbaugh D, Leard A, Bergman P, Klein M, Meleo K, Susaneck S . Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res. 2011; 72(12):1631-8. DOI: 10.2460/ajvr.72.12.1631. View

18.

Kawabe M, Mori T, Ito Y, Murakami M, Sakai H, Yanai T . Outcomes of dogs undergoing radiotherapy for treatment of oral malignant melanoma: 111 cases (2006-2012). J Am Vet Med Assoc. 2015; 247(10):1146-53. DOI: 10.2460/javma.247.10.1146. View

19.

Price M, Colvin Wanshura L, Yang J, Carlson J, Xiang B, Li G . CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res. 2011; 24(6):1148-57. PMC: 3426219. DOI: 10.1111/j.1755-148X.2011.00929.x. View

20.

Bergman P, McKnight J, Novosad A, Charney S, Farrelly J, Craft D . Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res. 2003; 9(4):1284-90. View